Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Plasma Exosomal RNA Signature for Predicting PSMA PET-Defined Bone Metastasis in Prostate Cancer: A Prospective, Multicenter Discovery, Development, and Validation Study

NCT07553754 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07553754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07553754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Plasma Exosomal RNA Signature for Predicting PSMA PET-Defined Bone Metastasis in Prostate Cancer: A Prospective, Multicenter Discovery, Development, and Validation Study
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Recruiting
Start date
March 12, 2026
Completion date
December 31, 2027
Enrollment
1,000 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker discovery and validation, bone metastasis, exosomal rna, liquid biopsy, prostate cancer (diagnosis), psma pet, treament-naive